Spotlight on teriflunomide

International MS Journal

Volumn 15, Issue 2, 2008, Pages 62-68

  Tallantyre, E ^a   Evangelou, N ^a   Constantinescu, Cris S ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Oral disease modifying agents; Pyrimidine synthesis inhibitor; Teriflunomide

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOOXYGENASE 2; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LAQUINIMOD; PROTEIN TYROSINE KINASE; PYRIMIDINE; ROQUINIMEX; TERIFLUNOMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HUMAN; IMAGE ANALYSIS; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSAL DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PROTEIN SYNTHESIS INHIBITION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; STRUCTURE ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CROTONIC ACIDS; HUMANS; MULTIPLE SCLEROSIS; TOLUIDINES;

EID: 51649112922     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 2007; 41: 1660-1668.
2. Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111: 35-44.
3. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 2007;156: 838-842.
4. de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996;26: 2067-2074.
5. Vandermeeren M, Janssens S, Borgers M, Geysen J. Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19-23.
6. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 2005;11: 43-48.
7. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64: 987-991.
8. Jonsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 2004;47: 2075-2088.
9. Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156: 3-9.
10. Lindemalm S, Savic RM, Karlsson MO, et al. Application of population pharmacokinetics to cladribine. BMC Pharmacol 2005; 5: 4.
11. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47: 273-289.
12. Elder RT, Xu X, Williams JW, et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159: 22-27.
13. Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993;334: 161-164.
14. Migita K, Miyashita T, Ishibashi H, et al. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1 beta stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol 2004;137: 612-616.
15. Siemasko K, Chong AS, Jack HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998;160: 1581-1588.
16. Xu X, Williams JW, Bremer EG, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270: 12398-12403.
17. Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996;52: 527-534.
18. Hoskin DW, Taylor RM, Makrigiannis AP, et al. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol 1998;20: 505-513.
19. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162: 2095-2102.
20. Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 2005;52: 2730-2739.
21. Hamilton LC, Volnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 1999; 127: 1589-1596.
22. Jankovic V, Samardzic T, Stosic-Grujicic S, et al. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol 2000;199: 73-80.
23. Miljkovic D, Samardzic T, Mostarica Stojkovic M, et al. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes, Brain Res 2001;889: 331-338.
24. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1 beta and metalloproteinases. Eur Cytokine Netw 1998;9: 663-668.
25. Dimitrova P, Skapenko A, Herrmann ML, et al. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002;169: 3392-3399.
26. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004;76: 950-960.
27. Bartlett RR, Anagnostopulos H, Zielinski T, et al. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993;14: 381-394.
28. O'Connor PW, Li D, Freedman MS. et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66: 894-900.
29. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39: 655-665.
30. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353: 259-266.
31. Kappos L, Miller DH, MacManus DG, et al. BG00012, a novel oral fumarate is effective in patients with relapsing-remitting multiple sclerosis. In: ECTRIMS. Madrid: Multiple Sclerosis, SAGE publications 2006.
32. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl Med 2006;355: 1124-1140.